Document:

Exhibit 10.8.2

 

 

 

January 24, 2021

 

Laurent Faracci

 

		Re:	Separation Agreement

 

Dear Laurent:

 

The purpose of this letter agreement (this
 “Agreement”) is to confirm your resignation from Butterfly Network, Inc. (the “Company”) as its
Chief Executive Officer as of January 23, 2021, and to set forth the terms of your resignation and separation from Company and
Insperity PEO Services, L.P. (“Insperity”). Payment of the Separation Benefits described below is contingent
on your agreement to and compliance with the terms of this Agreement. This Agreement shall become effective on the Effective Date
(as defined below).

 

		1.	Separation of Employment. You resigned your employment with Company effective
                                                                 as of January 23, 2021 (the “Separation Date”). You acknowledge and agree that from and after the
                                                                 Separation Date, you will not represent yourself as an employee or agent of Company or Insperity. As of the Separation Date, you shall
                                                                 have been deemed to have resigned from each and every office, position or responsibility in which you served for Company and
                                                                 each of its affiliates, subsidiaries or divisions, including as a director of Company.

 

		2.	Company Equity. You were granted options (each, an “Option”) to
purchase shares of Company’s common stock pursuant to the terms of the following four option agreements:

 

·        
Option No. 540-ISO Stock Option Grant Notice and Stock Option Agreement, dated April 23, 2020 (the “540-ISO Award”);

·        
Option No. 540-NQO Stock Option Grant Notice and Stock Option Agreement, dated April 23, 2020 (the “540-NQO Award”);

·        
Option No. 541 Stock Option Grant Notice and Stock Option Agreement, dated April 23, 2020 (the “541 Award”);
and

·        
Option No. 542 Stock Option Grant Notice and Stock Option Agreement, dated April 23, 2020 (the “542 Award”).

 

Each of the forgoing Options
is subject to the terms of Company’s 2012 Employee, Director and Consultant Equity Incentive Plan (the “Plan”).
Subject to Section 5, as of the Separation Date, you acknowledge and agree that the table below sets forth a complete and accurate
list of Options as of the Separation Date:

 

	Issuing Company	Grant Number	Grant Date	# of Shares Granted	# of Shares Vested	Type of Option
	Butterfly Network, Inc.	540-ISO	April 23, 2020	55,000	0	Time-Based
	Butterfly Network, Inc.	540-NQO	April 23, 2020	4,295,000	0	Time-Based
	Butterfly Network, Inc.	541	April 23, 2020	1,635,000	0	Performance-Based
	Butterfly Network, Inc.	542	April 23, 2020	1,635,000	0	Performance-Based

 

     

     

    

 

You acknowledge and agree that
as of the Separation Date, you are not vested in any of the shares under the 540-ISO Award or the 540-NQO Award and, subject to
Section 5, all unvested shares subject to the 540-ISO Award and the 540 NQO Award will be forfeited as of the Separation Date.
You and the Company acknowledge that the 541 Award and the 542 Award will remain outstanding in accordance with their terms through
April 23, 2021, the three month period following the Separation Agreement. You further acknowledge that: (a) the Company expects
to enter into the transactions contemplated by that certain Business Combination Agreement by and among Longview Acquisition Corp.
(“Parent”), a Delaware corporation, Clay Merger Sub, Inc., a Delaware corporation ("Merger Sub"),
and the Company (as amended from time to time, the "Business Combination Agreement") pursuant to which, among
other things, (i) Merger Sub will merge with and into the Company with the Company as the surviving company in the merger and (ii)
each share of the Company's capital stock (other than shares of the Company's Series A Preferred Stock) will automatically be converted
into the right to receive shares of Class A common stock, par value $0.0001 per share, of Parent, as set forth in, and subject
to, the Business Combination Agreement (the “Business Combination”); (b) the Business Combination is not and
will not result in a “2X Financing” (as that term is defined in the 541 Award) and is not and will not result in a
 “5X Financing” (as that term is defined in the 542 Award); (c) none of the shares subject to the 541 Award or the 542
Award will vest in connection with the consummation of the Business Combination or the surviving company’s shares becoming
publicly tradable securities as a result of the Business Transaction; and (d) if a 2X Financing or a 5X Financing does not occur
by April 23, 2021, neither the 541 Award or the 542 Award will vest and you will forfeit both the 541 Award and the 542 Award in
total to the Company on such date.

 

		3.	Affiliate Equity. Your offer letter from Company dated December 18, 2019 (the “Offer
Letter”) provided that, subject to the approval of the Board of Directors of Hyperfine Research, Inc. (“Hyperfine”),
you would receive an option to acquire up to 350,000 shares of common stock (the “Hyperfine Option”) and, subject
to the approval of the Board of Directors of 4Bionics, LLC (“4Bionics”), you would receive 409,000 Incentive
Units (the “4Bionics Unit Award”), in each case subject to vesting based on your continued employment with Company.
You and Company agree that you have not satisfied as of the Separation Date any of the vesting or forfeiture requirements on which
the foregoing equity awards would have been predicated; and you therefore do not have any rights to hold or acquire any shares
of common stock of Hyperfine or any Incentive Units of 4Bionics.

 

		4.	Relocation Payment. You will promptly repay to Company the net amount that you received
after withholding from the December 15, 2020 $161,864.70 relocation bonus. Once repaid, Company will deduct from your 2020 W-2
wages the gross amount of $161,864.70.

 

		5.	Separation Benefits. In exchange for the promises and release of claims contained
herein, Company shall provide you with the following (the “Separation Benefits”):

 

		(a)	A cash severance amount equal to $900,000 (the “Severance”), such amount representing
one (1) year of your base salary and a bonus equal to fifty-percent (50%) of your base salary. The Severance, less applicable withholdings,
will be paid on Company’s first payroll pay date occurring on or after the Effective Date.

 

		(b)	Notwithstanding the terms of the Offer Letter, Company will also pay you an amount equal to
                                                                      $150,000, such amount representing the bonus payable for 2020 (the “2020 Bonus”). The 2020 Bonus will be
                                                                      paid in a lump sum payment in February 2021, less all applicable federal, state, local and other legally required or
                                                                      authorized deductions. You acknowledge that the Company has the sole obligation to pay the amounts due under Sections 5(a) and (b), and that Insperity has no
obligation to pay the additional compensation, even though the payments may be processed through Insperity.

 

    	 	2	 

     

    

 

		(c)	Notwithstanding anything in any Option Agreement or Plan to the contrary: (x) the number of shares
subject to the 540-ISO Award and the 540-NQO Award that would have vested if you had remain employed through the one (1) year anniversary
of the Separation Date shall vest as of the Effective Date as set forth in the chart below (the “Vested Options”);
(y) the Vested Options shall remain exercisable until the five (5) year anniversary of the Separation Date; and (z) except as modified
in this Section, the 540-ISO Award and the 540-NQO Awards shall survive the execution of this Agreement continue to be governed
by the terms of the applicable Stock Option Agreement and the Plan:

 

	Issuing Company	Grant Number	Grant Date	# of Shares Granted	# of Shares Vested	Type of Option
	Butterfly Network, Inc.	540-ISO	April 23, 2020	55,000	19,244	Time-Based
	Butterfly Network, Inc.	540-NQO	April 23, 2020	4,295,000	1,503,247	Time-Based

 

You acknowledge
that except for the Separation Benefits, your final wages, and any accrued but unused vacation (each of which shall be paid to
you in accordance with Company’s regular payroll practices and applicable law), you are not now and shall not in the future
be entitled to any other compensation from Company or any of its affiliates, subsidiaries or divisions, without limitation, other
wages, commissions, bonuses, vacation pay, holiday pay, equity, units, stock, stock options, carve out, paid time off or any other
form of compensation or benefit.

 

		6.	COBRA Benefits. Regardless of whether you sign the Agreement, you shall have the
right to elect to continue your medical and dental benefits pursuant to the terms and conditions of COBRA. Your eligibility for
benefits under COBRA, the amount of such benefits, and the terms and conditions of such benefits, shall be determined by COBRA
statutory and regulatory guidelines. Subject to your timely election of continuation coverage under COBRA and your signing this
Agreement, Company will reimburse you or pay on your behalf the monthly premium payable to continue your and your eligible dependents’
participation in the Company’s group health plan for the twelve month period following the Separation Date, provided that
if you become eligible for coverage under a subsequent employer’s group health plan, the Company’s obligation to reimburse
you under this Section will immediately terminate. If the reimbursement of any COBRA premiums would violate the nondiscrimination
rules or cause the reimbursement of claims to be taxable under the Patient Protection and Affordable Care Act of 2010, together
with the Health Care and Education Reconciliation Act of 2010 (collectively, the “Act”) or Section 105(h) of
the Code, Company-paid premiums will be treated as taxable payments and be subject to imputed income tax treatment to the extent
necessary to eliminate any discriminatory treatment or taxation under the Act or Section 105(h) of the Code.

 

		7.	Unemployment Benefits. By virtue of your separation of employment, you shall be entitled
to apply for unemployment benefits. The determination of your eligibility for such benefits (and the amount of benefits to which
you may be entitled) shall be made by the appropriate state agency pursuant to applicable state law. Company agrees that it shall
not contest any claim for unemployment benefits by you. Company, of course, shall not be required to falsify any information.

 

		8.	Return of Property, Confidentiality, Non-Disparagement, and Related Matters. You
expressly acknowledge and agree to the following:

 

		(a)	You have returned to Company all documents (and any copies, duplicates, or replicas thereof), and
property, including, without limitation, any laptop computer that was provided to you by Company or any of its affiliates, including
4-Combinator, Inc., 4Catalyzer Corporation, Company’s and their respective divisions, affiliates, parents, subsidiaries and
related entities, and all of its and their owners, shareholders, partners, directors, officers, employees, trustees, agents, successors
and assigns (collectively, the “Company Affiliates”) during your employment with Company, and that you will
abide by any and all common law and/or statutory obligations relating to protection and non-disclosure of Company’s and Company
Affiliates’ trade secrets and/or confidential and proprietary documents and information.

 

    	 	3	 

     

    

 

		(b)	In the event that you receive an order, subpoena, request, or demand for disclosure of Company’s
or a Company Affiliate’s trade secrets and/or confidential and proprietary documents and information from any court or governmental
agency, or from a party to any litigation or administrative proceeding, unless prohibited by a court or government agency order,
you shall as soon as reasonably possible and prior to disclosure notify Company of the same, in order to provide Company with the
opportunity to assert its or a Company Affiliate’s respective interests in addressing or opposing such order, subpoena, request,
or demand.

 

		(c)	You agree that all information relating in any way to this Agreement, including the terms and amount
of financial consideration provided for in this Agreement, shall be held confidential by you and shall not be publicized or disclosed
to any person (other than an immediate family member, legal counsel or financial advisor, provided that any such individual to
whom disclosure is made agrees to be bound by these confidentiality obligations), business entity or government agency (except
as mandated by state or federal law).

 

		(d)	You previously executed a Non-Competition, Confidentiality and Intellectual Property Agreement
dated December 27, 2019 (the “Confidentiality Agreement”). The Confidentiality Agreement remains in full force
and effect and survives the termination of your employment with Company. You will honor and abide by the terms and provisions of
the Confidentiality Agreement.

 

		(e)	You will not make any statements that are disparaging about, or adverse to, the interests or
                                                                      business of Company or any Company Affiliate (including their respective officers, directors, employees, and direct or
                                                                      indirect shareholders) including, without limitation, any statements that disparage any person, product, service, finances,
                                                                      financial condition, capability or any other aspect of the business of Company or any Company Affiliate (including its
                                                                      officers, directors, employees, and direct or indirect shareholders). You further agree not to make any statements that are
                                                                      disparaging about, or adverse to, the interests or business of Glenview Capital Management, LLC, its subsidiaries and
                                                                      affiliates or any of their respective officers, directors, employees, and direct or indirect members or equity holders
                                                                      (“Glenview”). You also agree that through the closing date of the Business Combination and for 90 days
                                                                      thereafter, you will not make any public media statements with respect to the Business Combination, the parties to the
                                                                      Business Combination or your separation of employment without the prior approval of Company in any manner whatsoever
                                                                      (including through the use of any social networking sites, blogs, forums or any similar medium, including in response to
                                                                      inquiries from other users of such medium) whether directly or indirectly through a third party (and Company hereby approves
                                                                      statements that are consistent with the public statements made by Company).

 

		(f)	Your breach of any of the foregoing covenants by you shall constitute a material breach of this
Agreement and shall relieve Company of any further obligations hereunder and, in addition to any other legal or equitable remedy
available to Company, shall entitle Company to recover any Separation Benefits already paid or provided to you pursuant to Section
4 of this Agreement and result in the immediate forfeiture and termination of the Vested Options.

 

    	 	4	 

     

    

 

		(g)	Company and Parent will not make in any public press statement, and Company will cause each of
Company’s directors and executive officers and Parent’s directors and named executive officers not to make, any statements
that are disparaging about, or adverse to you.

 

		9.	Your Release of Claims.

 

		(a)	You hereby agree and acknowledge that by signing this Agreement and accepting the Separation
                                                                      Benefits, and for other good and valuable consideration provided for in this Agreement, you are waiving and releasing your
                                                                      right to assert any form of legal claim against Company and each of Insperity, 4-Combinator, Inc. and 4Catalyzer Corporation,
                                                                      each of the foregoing entities’ respective divisions, affiliates, parents, subsidiaries and related entities, including
                                                                      Hyperfine and 4Bionics, and all of the foregoing entities’ owners, shareholders, partners, directors, officers,
                                                                      employees, trustees, agents, successors and assigns (the “Company Parties”) whatsoever for any alleged
                                                                      action, inaction or circumstance existing or arising from the beginning of time through the Effective Date. Your waiver and
                                                                      release herein is intended to bar any form of legal claim, charge, complaint or any other form of action (jointly referred to
                                                                      as “Claims”) against Company or any of Company Parties seeking any form of relief including, without
                                                                      limitation, equitable relief (whether declaratory, injunctive or otherwise), the recovery of any damages or any other form of
                                                                      monetary recovery whatsoever (including, without limitation, back pay, front pay, compensatory damages, emotional distress
                                                                      damages, punitive damages, attorneys’ fees and any other costs) against Company or any Company Party, for any alleged
                                                                      action, inaction or circumstance existing or arising through the Effective Date. Without limiting the generality of the
                                                                      foregoing, you specifically waive and release Company and Company Parties from any waivable claim arising from or related to
                                                                      your employment relationship with Company through the Effective Date including, without limitation:

 

		(i)	Claims under any New York (or any other state) or federal discrimination, fair employment practices,
or other employment related statute, regulation or executive order (as amended through the Effective Date), including but not limited
to the Age Discrimination in Employment Act and Older Workers Benefit Protection Act (29 U.S.C. § 621 et seq.), the
Civil Rights Acts of 1866 and 1871 and Title VII of the Civil Rights Act of 1964 and the Civil Rights Act of 1991 (42 U.S.C.
 § 2000e et seq.), the Equal Pay Act (29 U.S.C. § 201 et seq.), the Genetic Information Non-Discrimination
Act (42 U.S.C. §2000ff et seq.), the Uniformed Services Employment and Reemployment Rights Act of 1994 (38 U.S.C.
 § 4301 et seq.), the Equal Pay Act (29 U.S.C. § 201 et seq.), the Lily Ledbetter Fair Pay Act, the Americans
with Disabilities Act of 1990 (42 U.S.C. § 12101 et seq.), the Rehabilitation Act of 1973, the New York State
Human Rights Law, the New York State Fair Credit Reporting Act, the New York State Correction Law, the New York Quarantine Leave
Law, the New York City Human Rights Law, including but not limited to the New York City Fair Chance Act, the New York City Earned
Sick and Safe Time Act, and the Stop Credit Discrimination in Employment Act, and any similar New York or other federal, state
or local statute.

 

    	 	5	 

     

    

 

		(ii)	Claims under any New York (or any other state) or federal employment related statute, regulation
or executive order (as amended through the Effective Date) relating to wages, hours or any other terms and conditions of employment,
including but not limited to the Fair Labor Standards Act (29 U.S.C. § 201 et seq.), the National Labor Relations Act
(29 U.S.C. § 151 et seq.), the Family and Medical Leave Act (29 U.S.C. §2601 et seq.), the Employee Retirement
Income Security Act of 1974 (29 U.S.C. § 1000 et seq.), COBRA (29 U.S.C. § 1161 et seq.), the Worker Adjustment
and Retraining Notification Act (29 U.S.C. § 2101 et seq.), and any similar New York or other federal, state or local
statute, and specifically including Claims related to salary, overtime, commissions, vacation pay, holiday pay, sick leave pay,
dismissal pay, bonus pay, severance pay, or retaliation.

 

		(iii)	Claims under any New York (or any other state) or federal common law theory, including, without
limitation, wrongful discharge, breach of express or implied contract, breach of the implied covenant of good faith and fair dealing,
privacy violations, invasion of privacy, promissory estoppel, unjust enrichment, breach of a covenant of good faith and fair dealing,
wrongful termination in violation of public policy, defamation, interference with contractual relations, intentional or negligent
infliction of emotional distress, fraudulent inducement, misrepresentation, deceit, fraud or negligence, rehire or reemployment
rights or any claim to attorneys’ fees under any applicable statute or common law theory of recovery.

 

		(iv)	Claims under any New York (or any other state) or federal statute, regulation or executive order
(as amended through the Effective Date) relating to whistleblower protections, violation of public policy, or any other form of
retaliation or wrongful termination, including but not limited to the Sarbanes-Oxley Act of 2002 and any similar New York or other
federal, state or local statute.

 

		(v)	Claims under any Company employment, compensation, bonus, benefit, stock option, incentive compensation,
restricted stock, and/or equity plan, program, policy, practice or agreement, including, without limitation, any Option, the Plan
and the Offer Letter other than as such rights have been specifically preserved under this Agreement;

 

		(vi)	Claims against Company or any Company Party arising out of or related to the alleged vesting of
shares under the 541 Award, the 542 Award or the Plan arising out of or in connection with the Business Combination;

 

		(vii)	Claims against Company, any Company Party, Hyperfine or 4Bionics arising out or related to the
Hyperfine Option or the 4Bionics Unit Award; or

 

		(viii)	Any other Claim arising under other local, state or federal law.

 

		(b)	Notwithstanding the foregoing, this Section 8 does not:

 

		(i)	Release Company or any Company Party from any obligation expressly set forth in this Agreement;

 

		(ii)	Waive or release any legal claims to vested benefits under Company’s employee benefit plans,
including Company’s 401(k) plan;

 

		(iii)	Waive or release any legal claims which you may not waive or release by law, including obligations
under workers’ compensation laws;

 

    	 	6	 

     

    

 

		(iv)	Waive or release any legal claims to indemnification under the indemnification agreement between
you and Company and Company’s director and officers’ insurance policies in effect from time to time;

 

		(iv)	Prohibit you from (i) filing a charge with, or participating in or assisting with an investigation
or proceeding conducted by, any governmental, regulatory and/or administrative entity or agency (including the Securities Exchange
Commission, the Equal Employment Opportunity Commission, the New York State Division of Human Rights, New York City Commission
on Human Rights, and/or OSHA); (ii) filing and, including as provided for under Section 21F of the Securities Exchange Act of 1934
(and Regulation 21F thereunder), maintaining the confidentiality of, a claim with a governmental, regulatory and/or administrative
entity or agency that is responsible for enforcing a law; or (iii) providing truthful information to a governmental, regulatory
and/or administrative entity or agency, law enforcement, or court, in response to compulsory legal process or as otherwise required
by law or legal process or as permitted by Section 21F of the Securities Exchange Act of 1934 (or Regulation 21F thereunder); provided,
however, you waive the right to recover any personal damages or other personal relief based on any claim, cause of action, demand,
lawsuit or similar that is waived pursuant to this Agreement and brought by you or on your behalf by any third party, including
as a member of any class or collective action, except that you do not waive any right to receive and fully retain any monetary
award from a government-administered whistleblower award program for providing information to a government agency, including but
not limited to damages or relief that may be available to you pursuant to such a program under the Securities Exchange Act of 1934.

 

		(d)	You further understand and expressly agree that this Agreement extends to all claims of every nature
and kind, known or unknown, suspected or unsuspected, past or present, arising from or attributable to any conduct of Company or
any Company Party. You acknowledge that you may later discover facts in addition to or different from those which you now believe
to be true with respect to the matters released in this Agreement. You, however, agree that you have taken that possibility into
account in reaching this Agreement, and that the release in this Agreement will remain in effect as a full and complete release
for all claims existing as of the date you execute this Agreement, notwithstanding the discovery or existence of additional or
different facts.

 

		(e)	You acknowledge and agree that, but for providing this waiver and release, you would not be receiving
the Separation Benefits provided to you under the terms of this Agreement.

 

		10.	Registration Rights Agreement and Lockup Agreement. If Company consummates the Business
Combination, (a) the Company hereby agrees that you may be a party to the Amended and Restated Registration Rights Agreement (the
 “Registration Rights Agreement”) contemplated by the Business Combination Agreement as a Butterfly Holder ( as defined
in the Registration Rights Agreement), and (b) you hereby agree and commit that during the Lock-Up Period, you shall not offer,
sell, contract to sell, pledge, grant any option to purchase, make any short sale or otherwise dispose of or distribute any shares
of Company’s Common Stock or any securities convertible into, exercisable for, exchangeable for or that represent the right
to receive shares of Common Stock, including the Vested Options, whether now owned or hereinafter acquired, that is owned directly
by you (including securities held as a custodian) or with respect to which you may have beneficial ownership within the rules and
regulations of the Securities and Exchange Commission (such securities that are subject to the Lock-up Period, the “Restricted
Securities”) and you agree to enter into a related lock up agreement in the form to be entered into by affiliates of
Company. The Lock-Up Period means: the period ending on the earlier of (i) 180 days after the closing of the Business Combination
(the “Closing”); and (ii) subsequent to the Closing, (x) if the last reported sale price of the Common Stock
equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like)
for any 20 trading days within any 30 consecutive trading days after the Closing or (y) the date on which Company completes a liquidation,
merger, stock exchange, reorganization or other similar transaction that results in all of Company’s public stockholders
having the right to exchange their shares of Common Stock for cash, securities or other property. The foregoing restriction is
expressly agreed to preclude you from engaging in any hedging or other transaction with respect to Restricted Securities which
is designed to or which reasonably could be expected to lead to or result in a sale or disposition of the Restricted Securities
even if such Restricted Securities would be disposed of by someone other than you. Such prohibited hedging or other transactions
include any short sale or any purchase, sale or grant of any right (including any put or call option) with respect to any of the
Restricted Securities, or with respect to any security that includes, relates to, or derives any significant part of its value
from such Restricted Securities. You hereby represent and warrant that you now have and for the duration of the Lock-up Period,
will continue to have good and marketable title to the Restricted Securities, free and clear of all liens, encumbrances, and claims
that could impact your ability to comply with the foregoing restrictions. You agree and consent to the entry of stop transfer instructions
with Company’s transfer agent and registrar against the transfer of any Restricted Securities during the Lock-up Period.

 

    	 	7	 

     

    

 

		11.	Waiver of Employment. You hereby waive and release forever any right or rights you
may have to employment with Company and any affiliate thereof at any time in the future, and agree not to seek or make application
for employment with Company or any affiliate thereof.

 

		12.	Reference Requests. To the extent Company receives any reference request for you
from a prospective employer, Company shall only provide dates of employment and last position held, and shall not otherwise characterize
or discuss the nature of or circumstances surrounding your separation from employment from Company.

 

		13.	Modification; Waiver; Severability. No variations or modifications hereof shall be
deemed valid unless reduced to writing and signed by the parties hereto. The failure of Company to seek enforcement of any provision
of this Agreement in any instance or for any period of time shall not be construed as a waiver of such provision or of Company’s
right to seek enforcement of such provision in the future. The provisions of this Agreement are severable, and if for any reason
any part hereof shall be found to be unenforceable, the remaining provisions shall be enforced in full.

 

		14.	Choice of Law and Venue; Jury Waiver. This Agreement shall be deemed to have been
made in New York and shall be governed by and construed in accordance with the laws of New York, without giving effect to conflict
of law principles. Both parties hereby waive and renounce in advance any right to a trial by jury in connection with such legal
action. 

 

		15.	Entire Agreement. You acknowledge and agree that, other than the Confidentiality
Agreement, the 540-ISO Award, and the 540-NQO Award, which are expressly incorporated herein by reference and stated as surviving
the signing of this Agreement, this Agreement supersedes any and all prior or contemporaneous oral and written agreements between
you and Company, and sets forth the entire agreement between you and Company.

 

    	 	8	 

     

    

 

		16.	Tax Matters. Company will withhold required federal, state, and local taxes from
any and all payments contemplated by this Agreement. Other than Company’s obligation and right to withhold, you will be responsible
for any and all taxes, interest, and penalties that may be imposed with respect to the payments contemplated by this Agreement
(including, but not limited to, those imposed under Section 409A of the Code (as defined below)). It is intended that payments
and benefits made or provided to you under this Agreement shall comply with Section 409A of the Internal Revenue Code of 1986 (as
amended) (the “Code”) or an exemption to Section 409A of the Code. You acknowledge and agree, however, that
Company does not guarantee the tax treatment or tax consequences associated with any payment or benefit arising under this Agreement,
including, without limitation, to consequences related to Section 409A of the Code. For purposes of the limitations on nonqualified
deferred compensation under Section 409A of the Code, each payment of compensation under this Agreement shall be treated as a separate
payment of compensation for purposes of applying the exclusion under Section 409A of the Code for short-term deferral amounts,
the separation pay exception or any other exception or exclusion under Section 409A of the Code.

 

		17.	Knowing and Voluntary Agreement. By executing this Agreement, you are acknowledging
that you have been afforded sufficient time to understand the terms and effects of this Agreement, that your agreements and obligations
hereunder are made voluntarily, knowingly and without duress, and that neither Company nor its agents or representatives have made
any representations inconsistent with the provisions of this Agreement.

 

	18.	ADEA Waiver.  You understand and agrees that with respect to any possible claim arising
under the Age Discrimination in Employment Act of 1967 (“ADEA”) you:
	 	 

		a.	Have had the opportunity to consider this Agreement for a full twenty-one (21) calendar days before
executing it (the “Review Period”), and if signing this Agreement before the end of the Review Period,
you have voluntarily waived the remainder of the Review Period.

 

		b.	Have carefully read and fully understands all of the provisions of this Agreement.

 

		c.	Are, through this Agreement, releasing Company and all of Company Parties from any and all claims
you may have against them.

 

		d.	Knowingly and voluntarily agree to all of the terms set forth in this Agreement.

 

		e.	Knowingly and voluntarily intend to be legally bound by the terms of this Agreement.

 

		f.	Were advised and hereby are advised in writing to consider the terms of this Agreement and to consult
with an attorney of your choice prior to executing this Agreement.

 

		g.	Understand that rights or claims under the ADEA that may arise due to acts or omissions that occur
after the Effective Date are not waived.

 

		h.	Understand that you have a period of seven (7) calendar days after the date that you sign this
Agreement to revoke your acceptance of the terms of this Agreement by actually completing delivery of (not merely dispatching)
a written notification by e-mail to Mary Miller, General Counsel, c/o Butterfly Network, Inc., mmiller@butterflynetinc.com

 

		19.	Execution and Delivery. Delivery of this Agreement by you to Company shall be effective
provided it is made no earlier than the Separation Date and no later than February 15, 2021. The executed Agreement should be delivered
to Company by scanning and then e-mailing it to Mary Miller, General Counsel, c/o Butterfly Network, Inc., mmiller@butterflynetinc.com.
You understand that you have seven (7) calendar days from the date you sign this Agreement to revoke your consent to this Agreement.
Any such revocation must be in writing and timely delivered by e-mail to the email address directly above. If you revoke this Agreement,
all of its provisions shall be void and unenforceable. This Agreement shall become effective on the eighth day after you sign it,
so long as you have not exercised your right to revoke it (such date, the “Effective Date”).

 

[Signature
Page Follows]

 

    	 	9	 

     

    

 

This Agreement may be signed on one or
more copies, each of which when signed shall be deemed to be an original, and all of which together shall constitute one and the
same Agreement. If the foregoing correctly sets forth our understanding, please sign, date and return the enclosed copy of this
Agreement in accordance with Section 18 above.

 

Sincerely,

 

BUTTERFLY NETWORK, INC.

 

	By:	/s/
    Jonathan M. Rothberg	 
	 	Jonathan M. Rothberg	 
	 	Chairman of the Board	 
	 	 	 
	Date:	January 24, 2021	 

 

 

Agreed and Acknowledged:

 

	
 

	/s/ Laurent Faracci	 
	Laurent Faracci	 
	 	 
	Date: 	January 24, 2021	 

 

    	 	10Exhibit 10.14

 

TODD FRUCHTERMAN (“Executive”)
and BUTTERFLY NETWORK, INC. (the “Company”)

EMPLOYMENT TERM SHEET

 

This Employment Term Sheet
is intended to summarize the preliminary, principal terms of a proposal by the Company to employ Executive as its Chief Executive
Officer. This term sheet is binding on the parties and will be effective and enforceable pending the negotiation and execution
of definitive documents between the parties. 

 

	Title:	Chief
    Executive Officer
	Reporting
    Relationship:	Reports
    to Board of Directors (the “Board”)
	Duties,
    Authorities Responsibilities:	Commensurate
    with the duties, authorities and responsibilities of persons in similar capacities in similarly sized companies, and such
    other duties, authorities and responsibilities as the Company may designate from time to time that are not inconsistent with
    Executive’s position.  Executive shall devote his best efforts and substantially all of his business time
    to the performance of his duties as CEO.
	Director:	During
    the Term, the Company will propose to the shareholders of the Company the election and reelection of Executive as a member
    of the Board.  Executive will be provided indemnification commensurate with the indemnification provided to other
    directors.   
	Term:	Employment
    as the Company’s Chief Executive Officer will begin upon execution of a definitive employment agreement or upon a mutually
    agreed upon later start date (the “Effective Date”) and will continue “at will” unless and until terminated
    by either party in accordance with the “Termination” provisions set forth below.
	Compensation:	Base
                                         Salary: $750,000 per annum, payable according
                                         the Company’s customary payroll practices. Executive will be eligible for a reasonable
                                         annual growth in compensation under the oversight and judgment of the Compensation Committee
                                         and the approval of the Board of Directors.

 

Annual
Bonus: Target bonus equal to 100% of the then-current Base Salary based on performance
metrics determined by the Board after consultation with Executive. The Annual Bonus will scale based on exceeding or partially
achieving annual performance metrics, subject to a cap of 200% of the then-current Base Salary. 

 

Reimbursement Bonus. The Company will pay to Executive
a Reimbursement Bonus having a net, after tax amount after withholding and payroll tax equal to $1,583,000 within five (5) business
days of the Effective Date, which net amount Executive will use to repay his existing legal obligation to his current employer.
The Executive will file with the applicable federal and state taxing authorities for all appropriate refunds in connection with
the repayment of his obligation and the resulting reduction in his 2020 gross income as a result of the repayment to his current
employer and will pay all such reimbursements not otherwise payable to his current employer over to the Company. Notwithstanding
the foregoing, Executive and the Company agree to cooperate with each other to structure the Reimbursement Bonus to be tax efficient
for each of the Company and Executive and minimize its cost to the Company and to the Executive, including by approaching the
Executive’s current employer to accept repayment of the net amount of the Executive’s obligation and to adjust Executive’s
2020 income accordingly.

 

     

     

    

 

		
        Signing
        Bonus: $1,000,000, payable to executive
        in two equal payments of $500,000. The initial payment of $500,000 would be made to Executive on the Company’s next
        payroll period following the Effective Date and the second and final payment of $500,000 would be made to executive on
        the next payroll period following the first anniversary of the Effective Date. The Signing Bonus will be subject to repayment
        if Executive is terminated for Cause or resigns without Good Reason on or prior to the first anniversary of the Effective
        Date.

         

        Initial
        Equity Award: The Company will grant Executive an initial option award to purchase 1,500,000 shares of the Company’s
        Common Stock at an exercise price equal to the shares’ fair market value on the grant date (expected to be approximately
        $15.87 per 409A valuation). The options will vest 25% on the first anniversary of the Effective Date and then in equal
        monthly installments over the next three years. 

         

        In
        addition, the Company will grant Executive a restricted stock unit award to receive 1,000,000 shares of the Company’s
        Common Stock. The RSU’s will vest 25% on each of the first four anniversaries of the Effective Date.

         

        Additional
        Equity Awards:  Executive will be eligible for annual equity awards subject to such time and performance vesting
        as determined by the Compensation Committee at the time of such grant. For the 2021 performance year, Executive will receive
        an award with a fair market value of $2,300,000 on the grant date, 50% in the form of stock options and 50% in the form
        of restricted stock units, which will vest over three years pursuant to the time-based and performance criteria determined
        by the Compensation Committee. Vesting criteria for future awards: (i) performance vesting not to exceed 50% of the value
        of any annual equity award and (ii) time based and performance-based vesting not to differ materially from performance
        measures applied to rest of management team.

         

        Employee
        Benefits: Executive will be eligible to participate in plans and perquisites sponsored by the Company. The Company
        acknowledges that Executive will manage his vacation in accordance with the Company’s flexible vacation policy (and
        the Executive’s use of annual vacation time of six weeks or less will not be deemed a breach of his duties to the
        Company). The Company will reimburse Executive for reasonable, customary relocation expenses and legal fees related to
        negotiation of these employment terms. Perquisites to include (i) annual reimbursement to Executive for all reasonable
        expenses related to the preparation and finalization of Executive’s tax returns for the 2020 and 2021 tax years,
        and (ii) an allowance in 2021 of $20,000 for expenses related to estate planning.

         

        Business
        Travel: At all times during the Term, Executive is authorized to conduct all business-related travel in Business Class
        accommodations. 

         

    2

     

    

 

	Termination:	
        Executive’s employment
        may be terminated:

         

        ·     
        By the Company because of Executive’s death.

         

        ·     
        By the Company because Executive is Disabled. Disabled means that Executive is unable
        to perform the essential functions of his position as CEO, with or without a reasonable accommodation, for a period of 120 calendar
        days within any rolling 12-month period (whether or not consecutive) or is eligible for benefits under a long-term disability plan
        sponsored by the Company.

         

        ·     
        By the Company for Cause. Cause means: (i) willful misconduct or gross negligence in the
        performance of Executive’s duties as Chief Executive Officer; (ii) refusal to follow the lawful directions of the Board;
        (iii) breach of a fiduciary duty owed to the Company or its shareholders; (iv) fraud, embezzlement or other material dishonesty
        with respect to the Company; (v) violation of applicable federal, state or local law or regulation governing the Company’s
        business; (vi) commission, conviction, plea of nolo contendere, guilty plea, or confession to a crime based upon an act
        of fraud, embezzlement or dishonesty or to a felony; (vii) habitual abuse of alcohol or any controlled substance or reporting to
        work under the influence of alcohol or any controlled substance (other than a controlled substance that Executive is properly taking
        under a current prescription), (viii) misappropriation (or attempted misappropriation) by Executive of any material assets or business
        opportunities of the Company or any of its subsidiaries or affiliates; (ix) a material failure to comply with the Company’s
        written policies or rules, as they may be in effect from time to time during Executive’s employment, including policies and
        rules prohibiting discrimination or harassment; or (x) a material breach of this Agreement, the Non-Competition, Confidentiality
        and Intellectual Property Agreement or any other written agreement between the Company or one of its subsidiaries and Executive,
        provided that Executive will have 30 days after notice from the Board to cure a failure or a breach under (ix) or (x), if curable.

         

        ·     
        By the Company without Cause.

         

        ·     
        By Executive with Good Reason. Good Reason means: means the occurrence of any of the following
        events without Executive’s consent; provided, that any resignation by Executive due to any of the following conditions will
        only be deemed for Good Reason if: (i) Executive gives the Board written notice of the intent to terminate for Good Reason within
        30 days following the first occurrence of the event that Executive believes constitutes Good Reason; (ii) the Company fails to
        cure, if curable, such event within 30 days following receipt of Executive’s written notice; and (iii) Executive actually
        resigns his employment within 60 days after delivering his notice to the Board: (a) a material reduction of Executive’s Base
        Salary as in effect immediately prior to the reduction; (b) a material reduction by the Company of Executive’s Target Annual
        Bonus as in effect immediately prior to the reduction, provided a compensation plan change that affects similarly all employees
        at similar levels will not constitute Good Reason; (c) a material reduction in Executive’s authority, duties or responsibilities,
        provided however, following a Change in Control Event, a change in job title or reporting relationship without a reduction in Executive’s
        base salary or annual bonus target will not constitute Good Reason; (d) relocation of the offices at which Executive is required
        to work to a location that would increase Executive’s one-way commute by more than 50 miles; or (e) failure of Executive
        to be re-elected to Board of the Company for any period during the Term. 

         

        ·     
        By Executive without Good Reason.

         

 

    3

     

    

 

	Compensation Upon Termination:	
        ·If
        the Company terminates Executive’s employment because of his death, because he is Disabled, or for Cause, or Executive resigns
        without Good Reason, Executive will receive:

         

        o     accrued
        and unpaid Base Salary;

         

        o     any
        earned, but unpaid annual bonus; and

         

        o     un-reimbursed
        expenses (the “Accrued Obligations”)

         

        o     only
        in the event of termination because of Executive’s death or because he is Disabled, such additional amount of initial sign-on
        restricted stock and option grants that represents no less than 50% of the initial grant amounts.

         

        ·If,
        other than during a Change in Control Period:

         

        (i)     the
        Company terminates Executive’s employment without Cause; or

         

        (ii)     Executive
        resigns with Good Reason;

         

        Executive will receive:

         

        o     the
        Accrued Obligations;

         

        o     Severance
        equal to 12 months Base Salary and Target Bonus, paid as continued salary over 12 months;

         

        o     Payment
        of an amount equal to COBRA premiums for 12 months; and

         

        o     12
        months additional vesting of outstanding time-based vesting equity awards.

         

        o     100%
        accelerated vesting for the initial sign-on restricted stock unit award of 1,000,000 shares of the Company’s Common Stock.

         

        ·If,
        during a Change in Control Period, the Company terminates Executive’s employment without Cause or if Executive resigns
        with Good Reason, Executive will receive:

         

        o     the
        Accrued Obligations;

         

        o     Severance
        equal to 2.0 times the sum of the Base Salary and Target Bonus, paid as continued salary over 24 months;

         

        o     Payment
        of an amount equal to COBRA premiums for 24 months; and

         

        o     100%
        accelerated vesting for all outstanding equity awards with time-based vesting.

         

        o     If
        Executive’s termination is effective during a Change in Control Period, but prior to the closing of the Change in Control
        Event, any outstanding equity awards with performance-based vesting will remain eligible to vest in connection with the closing
        of the Change in Control.

         

        

 

    4

     

    

 

		
         The “Change in Control Period”
        is the period commencing on the date beginning 90 days prior to the public announcement of a Change in Control Event and
        ending on the two year anniversary of the consummation of a Change in Control Event.

         

        A “Change in Control Event” means the
        occurrence of any of the following:

         

        ·     any
        person or group of persons (other than the Company or its affiliates) becomes the owner, directly or indirectly, of securities
        of the Company representing more than 50% of the combined voting power of the Company’s then outstanding voting securities
        (the “Outstanding Company Voting Securities”) (but excluding any bona fide financing event in which securities are
        acquired directly from the Company); or

         

        ·     the
        consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation (i) that
        results in the Outstanding Company Voting Securities immediately prior thereto continuing to represent (either by remaining outstanding
        or by being converted into voting securities of the surviving entity) at least 50% of the combined voting power of the Outstanding
        Company Voting Securities (or such surviving entity or, if the Company or the entity surviving such merger is then a subsidiary,
        the ultimate parent thereof) outstanding immediately after such merger or consolidation, or (ii) immediately following which
        the individuals who comprise the Board immediately prior thereto constitute at least a majority of the Board of the entity surviving
        such merger or consolidation or, if the Company or the entity surviving such merger is then a subsidiary, the ultimate parent thereof;
        or

         

        ·     the
sale or disposition by the Company of all or substantially all of the Company’s assets, other than (i) a sale or disposition
by the Company of all or substantially all of the Company’s assets to an entity, at least 50% of the combined voting power
of the voting securities of which are owned directly or indirectly by stockholders of the Company following the completion of
such transaction in substantially the same proportions as their ownership of the Company immediately prior to such sale or (ii) a
sale or disposition of all or substantially all of the Company’s assets immediately following which the individuals who
comprise the Board immediately prior thereto constitute at least a majority of the board of directors of the entity to which such
assets are sold or disposed or, if such entity is a subsidiary, the ultimate parent thereof;

        

        provided that in each case, a transaction will not be deemed a Change in Control unless (x) the transaction qualifies as a
        change in control within the meaning of Code Section 409A, and (y) following the conclusion of the transaction or series
        of integrated transactions, the holders of the Company’s Series A Preferred Stock immediately prior to such transaction
        or series of transactions continue to have substantially the same proportionate ownership in an entity which owns all or substantially
        all of the assets of the Company immediately following such transaction or series of transactions.

         

        All severance benefits will be conditioned on Executive signing
        a general release of claims in the form to be attached to the definitive employment agreement.

         

 

    5

     

    

 

	Post-Employment Restrictions:	Executive will be subject to a Company-standard Non-Competition, Confidentiality and Intellectual Property Agreement, which includes covenants to protect confidential information and to assign intellectual property to the Company, a one year post-employment covenant not to compete with the Company in the United States in the field of ultrasound technologies, devices and applications, a two year post-employment covenant not to solicit or service the Company’s customers or prospective customers to or for a competing business, and a two year post-employment covenant not to solicit or hire the Company’s employees or contractors.   
	 	 
	Miscellaneous:	
        Indemnification:
        The Company will continue to indemnify Executive as provided under Executive’s existing indemnification agreement with the
        Company.

         

        Disputes: Disputes will be subject to arbitration before JAMS,
        provided that disputes under the Non-Competition, Confidentiality and Intellectual Property Agreement will be subject to enforcement
        in the courts.

         

        Governing
        Law: New York

 

	Executed as of January 23, 2021	 	 
	 	 	 	 
	BUTTERFLY NETWORK, INC.	 	TODD FRUCHTERMAN
	 	 	 	 
	By: 	 /s/
    Jonathan M. Rothberg	 	/s/ Todd Fruchterman
	Name:	 Jonathan M. Rothberg	 	 
	Title: 	 Chairman of the Board	 	 

 

    6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}]]